References
1. Seyahi E, Yurdakul S. Behçet’s Syndrome and Thrombosis. Mediterr J
Hematol Infect Dis. 2011;3(1):e2011026.
2. Verity DH. Behcet’s disease: from Hippocrates to the third
millennium. Br J Ophthalmol. 2003 Sep 1;87(9):1175–83.
3. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P.
Behçet’s disease physiopathology: a contemporary review. Autoimmun
Highlights. 2016 Dec;7(1):4.
4. Paudyal B, Gyawalee M, Manandhar A, Sigdel keshav raj. Behçet’s
Disease: An Account of Three Cases. J Nepal Health Res Counc. 2012 Sep
1;10:250–3.
5. Alpsoy E. Behçet’s disease: A comprehensive review with a focus on
epidemiology, etiology and clinical features, and management of
mucocutaneous lesions. J Dermatol. 2016 Jun;43(6):620–32.
6. Pande I, Uppal SS, Kailash S, Kumar A, Malavtya AN. BEHÇET’S DISEASE
IN INDIA: A CLINICAL, IMMUNOLOGICAL, IMMUNOGENETIC AND OUTCOME STUDY.
Rheumatology. 1995;34(9):825–30.
7. Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease
manifestations, management, and advances in treatment. Nat Clin Pract
Rheumatol. 2007 Mar;3(3):148–55.
8. Sachdev N, Kapali N, Singh R, Gupta V, Gupta A. Spectrum of Behçet’s
disease in the Indian population. Int Ophthalmol. 2009
Dec;29(6):495–501.
9. Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel
G. Dual effects of testosterone in Behcet’s disease: implications for a
role in disease pathogenesis. Genes Immun. 2016 Sep;17(6):335–41.
10. Yazici H, Esen F. Mortality in Behçet’s syndrome. Clin Exp
Rheumatol. 2008 Oct;26(5 Suppl 51):S138-140.
11. de Menthon M, LaValley MP, Maldini C, Guillevin L, Mahr A.HLA-B51/B5 and the risk of Behçet’s disease: A systematic review
and meta-analysis of case-control genetic association studies. Arthritis
Rheum. 2009 Oct 15;61(10):1287–96.
12. Gül A. Genetics of Behçet’s disease: lessons learned from genomewide
association studies. Curr Opin Rheumatol. 2014 Jan;26(1):56–63.
13. Internationalstudygroupforbehc. Criteria for diagnosis of Behcet’s
disease. The Lancet [Internet]. 1990 May [cited 2021 Jul
27];335(8697). Available from:
https://linkinghub.elsevier.com/retrieve/pii/014067369092643V
14. International Team for the Revision of the International Criteria
for Behçet’s Disease (ITR-ICBD), Davatchi F, Assaad-Khalil S, Calamia
KT, Crook JE, Sadeghi-Abdollahi B, et al. The International Criteria for
Behçet’s Disease (ICBD): a collaborative study of 27 countries on the
sensitivity and specificity of the new criteria. J Eur Acad Dermatol
Venereol. 2014 Mar;28(3):338–47.
15. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al.
Genome-wide association study identifies GIMAP as a novel susceptibility
locus for Behçet’s disease. Ann Rheum Dis. 2013 Sep;72(9):1510–6.
16. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et
al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J
Med. 2016 Sep 8;375(10):932–43.